Tibotec Pharmaceuticals, Ireland clinical trials

Acquired by Johnson & Johnson, Apr 2002 · source ↗

The registry lists 77 studies whose lead sponsor is Tibotec Pharmaceuticals, Ireland. 0 are recruiting or about to start. Per ClinicalTrials.gov, last updated Jun 4, 2026.

Studies

Recruiting first, then most recently updated. Showing 50 of 77. List all 77 → · All Johnson & Johnson studies →

• The TMC125-C214 Study Provides Early Access to TMC125 for HIV-1 Infected Patients Who Have Failed Multiple Antiretroviral Regimens and Will Also Gather Information on the Long-term Safety and Tolerability of TMC125 Combined With Other Antiretroviral DrugsApproved for marketingNCT00354627

  Sponsor listed in the registry: Tibotec Pharmaceuticals, Ireland · First submitted after Tibotec Pharmaceuticals, Ireland became part of Johnson & Johnson

• PEPI-TiDP23-C104 is a First in Human Study With a Single Dose Escalation Part and a Multiple Dosing Part for Compounds TMC589337 and TMC589354.WithdrawnNCT00908414Phase 1

  Sponsor listed in the registry: Tibotec Pharmaceuticals, Ireland · First submitted after Tibotec Pharmaceuticals, Ireland became part of Johnson & Johnson

• TMC114-C202: A Study of Safety, Efficacy, and Tolerability of TMC114 and Low Dose Ritonavir in HIV-1 Infected PatientsCompletedNCT00071097Phase 2

  Sponsor listed in the registry: Tibotec Pharmaceuticals, Ireland · First submitted after Tibotec Pharmaceuticals, Ireland became part of Johnson & Johnson

• TMC278-TiDP6-C215: A Clinical Trial in Treatment Naive HIV-subjects Patients Comparing TMC278 to Efavirenz in Combination With 2 Nucleoside/Nucleotide Reverse Transcriptase InhibitorsCompletedNCT00543725Phase 3

  Sponsor listed in the registry: Tibotec Pharmaceuticals, Ireland · First submitted after Tibotec Pharmaceuticals, Ireland became part of Johnson & Johnson

• TMC278-TiDP6-C209: A Clinical Trial in Treatment Naive HIV-1 Patients Comparing TMC278 to Efavirenz in Combination With Tenofovir + Emtricitabine.CompletedNCT00540449Phase 3

  Sponsor listed in the registry: Tibotec Pharmaceuticals, Ireland · First submitted after Tibotec Pharmaceuticals, Ireland became part of Johnson & Johnson

• TMC114-C214: Trial of TMC114 Administered With Low Dose Ritonavir (RTV) in HIV-1 Infected Treatment Experienced PatientsCompletedNCT00110877Phase 3

  Sponsor listed in the registry: Tibotec Pharmaceuticals, Ireland · First submitted after Tibotec Pharmaceuticals, Ireland became part of Johnson & Johnson

• TMC125-TiDP35-C213: Safety and Antiviral Activity of Etravirine (TMC125) in Treatment-Experienced, HIV Infected Children and AdolescentsCompletedNCT00665847Phase 2

  Sponsor listed in the registry: Tibotec Pharmaceuticals, Ireland · First submitted after Tibotec Pharmaceuticals, Ireland became part of Johnson & Johnson

• A Study to Assess the Long-term Safety and Tolerability of TMC114/Rtv in HIV-1 Infected Participants After Rolling-over From Other TMC114 TrialsCompletedNCT02187107Phase 2

  Sponsor listed in the registry: Tibotec Pharmaceuticals, Ireland · First submitted after Tibotec Pharmaceuticals, Ireland became part of Johnson & Johnson

• A Study to Assess the Anti-viral Activity, Safety, Tolerability and Pharmacokinetics of TMC435350 in Participants Infected With Hepatitis C-Virus (HCV)CompletedNCT00812331Phase 2

  Sponsor listed in the registry: Tibotec Pharmaceuticals, Ireland · First submitted after Tibotec Pharmaceuticals, Ireland became part of Johnson & Johnson

• A Study of TMC278 in Human Immunodeficiency Virus Type 1 Infected Patients, Who Are Not Treated With Antiretroviral MedicinesCompletedNCT00110305Phase 2

  Sponsor listed in the registry: Tibotec Pharmaceuticals, Ireland · First submitted after Tibotec Pharmaceuticals, Ireland became part of Johnson & Johnson

• TMC125-C206: A Phase III Study to Investigate the Efficacy, Tolerability and Safety of TMC125 as Part of an Antiretroviral Regimen, Including TMC114/Ritonavir and an Investigator-selected Optimized Background, in HIV-1 Infected Patients With Limited to no Treatment Options.CompletedNCT00254046Phase 3

  Sponsor listed in the registry: Tibotec Pharmaceuticals, Ireland · First submitted after Tibotec Pharmaceuticals, Ireland became part of Johnson & Johnson

• An Open Label Trial of TMC114/RTV in HIV-1 Infected, Treatment-experienced Subjects.CompletedNCT00081588Phase 2

  Sponsor listed in the registry: Tibotec Pharmaceuticals, Ireland · First submitted after Tibotec Pharmaceuticals, Ireland became part of Johnson & Johnson

• A Study of TMC435 in Combination With Pegylated Interferon Alp\Fa-2a and Ribavirin in Patients Infected With Genotype 1 Hepatitis C Virus Who Never Received TreatmentCompletedNCT00882908Phase 2

  Sponsor listed in the registry: Tibotec Pharmaceuticals, Ireland · First submitted after Tibotec Pharmaceuticals, Ireland became part of Johnson & Johnson

• A Safety and Effectiveness Study of TMC435 in Chronic, Genotype 1, Hepatitis C Patients Who Failed to Previous Standard TreatmentCompletedNCT00980330Phase 2

  Sponsor listed in the registry: Tibotec Pharmaceuticals, Ireland · First submitted after Tibotec Pharmaceuticals, Ireland became part of Johnson & Johnson

• A Study of TMC435350 Administered With or Without Standard of Care Therapy in Participants With Genotype 1 Hepatitis C Virus InfectionCompletedNCT00561353Phase 2

  Sponsor listed in the registry: Tibotec Pharmaceuticals, Ireland · First submitted after Tibotec Pharmaceuticals, Ireland became part of Johnson & Johnson

• An Open-label Trial With TMC125 in Patients Who Have Virologically Failed in a DUET Trial (TMC125-C206 or TMC125-C216).CompletedNCT00359021Phase 3

  Sponsor listed in the registry: Tibotec Pharmaceuticals, Ireland · First submitted after Tibotec Pharmaceuticals, Ireland became part of Johnson & Johnson

• TMC435 HPC1004 - Phase I Study Investigating the Pharmacokinetics of TMC435 in Healthy Chinese VolunteersCompletedNCT01224197Phase 1

  Sponsor listed in the registry: Tibotec Pharmaceuticals, Ireland · First submitted after Tibotec Pharmaceuticals, Ireland became part of Johnson & Johnson

• A Safety Study to Evaluate the Antiviral Activity of Darunavir in Combination With Ritonavir in HIV 1 Infected ChildrenCompletedNCT00919854Phase 2

  Sponsor listed in the registry: Tibotec Pharmaceuticals, Ireland · First submitted after Tibotec Pharmaceuticals, Ireland became part of Johnson & Johnson

• TMC114-C226: An Early Access Program to Evaluate the Long-term Safety and Tolerability of TMC114 Combined With a Low Dose of Ritonavir (TMC114/r) With Other Antiretrovirals, for HIV-1 Infected Patients Who Have Failed Multiple Antiretroviral Regimens.Approved for marketingNCT00245739

  Sponsor listed in the registry: Tibotec Pharmaceuticals, Ireland · First submitted after Tibotec Pharmaceuticals, Ireland became part of Johnson & Johnson

• TMC114-TiDP3-C176 - A Study in Healthy Volunteers Investigating the Bioequivalence Between Two Commercially Available 400-mg Tablets to One New 800-mg Tablet of Darunavir (DRV) in the Presence of Low-dose Ritonavir Under Fed and Fasted ConditionsCompletedNCT01308658Phase 1

  Sponsor listed in the registry: Tibotec Pharmaceuticals, Ireland · First submitted after Tibotec Pharmaceuticals, Ireland became part of Johnson & Johnson

• A Study to Investigate the Potential Pharmacokinetic Interaction Between TMC435 and MethadoneCompletedNCT00915564Phase 1

  Sponsor listed in the registry: Tibotec Pharmaceuticals, Ireland · First submitted after Tibotec Pharmaceuticals, Ireland became part of Johnson & Johnson

• TMC435-TiDP16-C126 - Trial to Investigate the Effect of Severe Renal Impairment on the Pharmacokinetics and Safety of TMC435CompletedNCT01381835Phase 1

  Sponsor listed in the registry: Tibotec Pharmaceuticals, Ireland · First submitted after Tibotec Pharmaceuticals, Ireland became part of Johnson & Johnson

• TMC435-TiDP16-C113: A Study to Investigate the Effect of Hepatic Impairment on the Pharmacokinetics of TMC435CompletedNCT01046058Phase 1

  Sponsor listed in the registry: Tibotec Pharmaceuticals, Ireland · First submitted after Tibotec Pharmaceuticals, Ireland became part of Johnson & Johnson

• A Study of Drug-drug Interaction Between Ritonavir and TMC435350 in Healthy VolunteersCompletedNCT01891851Phase 1

  Sponsor listed in the registry: Tibotec Pharmaceuticals, Ireland · First submitted after Tibotec Pharmaceuticals, Ireland became part of Johnson & Johnson

• TMC114-TiDP3-C182 - A Study to Compare the Oral Bioavailability of a 800 mg Prototype Tablet Formulation of Darunivar (DRV) to That of the 400 mg Commercial Tablet Formulation in the Presence of Low Dose Ritonavir, Under Fasted and Fed ConditionsCompletedNCT01052883Phase 1

  Sponsor listed in the registry: Tibotec Pharmaceuticals, Ireland · First submitted after Tibotec Pharmaceuticals, Ireland became part of Johnson & Johnson

• A Phase 2 Study to Evaluate Pharmacokinetics, Safety and Efficacy of TMC114/Ritonavir (Rtv) in Human Immunodeficiency Virus (HIV)-1 Infected Children and AdolescentsCompletedNCT00355524Phase 2

  Sponsor listed in the registry: Tibotec Pharmaceuticals, Ireland · First submitted after Tibotec Pharmaceuticals, Ireland became part of Johnson & Johnson

• TMC114-C211: Trial of an Investigational Protease Inhibitor TMC114 With Ritonavir ("TMC114/r") in HIV-1 Infected Patients Who Have Never Been Treated With Antiretroviral Medications.CompletedNCT00258557Phase 3

  Sponsor listed in the registry: Tibotec Pharmaceuticals, Ireland · First submitted after Tibotec Pharmaceuticals, Ireland became part of Johnson & Johnson

• A Study With TMC125 in Human Immunodeficiency Virus (HIV) Type 1 Infected Patients, Who Were Treated With TMC125 Arm in a Sponsor-Selected TMC125 StudyCompletedNCT00128830Phase 2

  Sponsor listed in the registry: Tibotec Pharmaceuticals, Ireland · First submitted after Tibotec Pharmaceuticals, Ireland became part of Johnson & Johnson

• A Study to Determine the Antiviral Activity of TMC310911 When Administered With Ritonavir in Treatment-Naive Human Immunodeficiency Virus - Type 1 (HIV-1) Infected PatientsCompletedNCT00838162Phase 2

  Sponsor listed in the registry: Tibotec Pharmaceuticals, Ireland · First submitted after Tibotec Pharmaceuticals, Ireland became part of Johnson & Johnson

• TMC435-TiDP16-C117: The Effect of TMC435 on the Results of Electrocardiograms (Electric Recording of the Heart) in Healthy VolunteersCompletedNCT01269294Phase 1

  Sponsor listed in the registry: Tibotec Pharmaceuticals, Ireland · First submitted after Tibotec Pharmaceuticals, Ireland became part of Johnson & Johnson

• TMC435-TiDP16-C125 - Study in Healthy Volunteers to Evaluate the Potential of TMC435 to Increase the Sensitivity of the Skin Towards Exposure to Sun LightCompletedNCT01124799Phase 1

  Sponsor listed in the registry: Tibotec Pharmaceuticals, Ireland · First submitted after Tibotec Pharmaceuticals, Ireland became part of Johnson & Johnson

• TMC435350-TiDP16-C105: Phase I, 3-way Crossover, Drug-drug Interaction Between TMC435350 and Rifampin After Multiple Dosing.CompletedNCT00741169Phase 1

  Sponsor listed in the registry: Tibotec Pharmaceuticals, Ireland · First submitted after Tibotec Pharmaceuticals, Ireland became part of Johnson & Johnson

• TMC435-TiDP16-C119 - A Study Comparing 2 New Capsule Formulations of TMC435 to an Established Capsule Formulation and Evaluating the Respective Blood Levels of TMC435 Following Single Dose AdministrationCompletedNCT01134718Phase 1

  Sponsor listed in the registry: Tibotec Pharmaceuticals, Ireland · First submitted after Tibotec Pharmaceuticals, Ireland became part of Johnson & Johnson

• TMC435-TiDP16-C112 - Interaction Trial With AntidepressantsCompletedNCT01090700Phase 1

  Sponsor listed in the registry: Tibotec Pharmaceuticals, Ireland · First submitted after Tibotec Pharmaceuticals, Ireland became part of Johnson & Johnson

• TMC649128HPC1001 - First In-human Trial to Examine Safety, Tolerability, and Pharmacokinetics (How the Drug is Absorbed Into the Bloodstream) of Increasing Single Oral Doses of TMC649128 in Healthy VolunteersCompletedNCT01288677Phase 1

  Sponsor listed in the registry: Tibotec Pharmaceuticals, Ireland · First submitted after Tibotec Pharmaceuticals, Ireland became part of Johnson & Johnson

• TMC647055HPC1001 - First-in-human Trial to Examine Safety, Tolerability and Pharmacokinetics (How the Drug is Absorbed Into the Bloodstream) of Increasing Single Oral Doses and of Increasing Repeated Oral Doses of TMC647055 in Healthy Volunteers and in Hepatitis C Virus Infected PatientsCompletedNCT01202825Phase 1

  Sponsor listed in the registry: Tibotec Pharmaceuticals, Ireland · First submitted after Tibotec Pharmaceuticals, Ireland became part of Johnson & Johnson

• A Study to Compare Effectiveness and Safety of Darunavir/Ritonavir (DRV/Rtv) 800mg/100mg Once Daily Versus DRV/Rtv 600mg/100mg Twice Daily in Early Treatment-Experienced HIV-1 Infected Patients (ODIN)CompletedNCT00524368Phase 3

  Sponsor listed in the registry: Tibotec Pharmaceuticals, Ireland · First submitted after Tibotec Pharmaceuticals, Ireland became part of Johnson & Johnson

• A Study in Healthy Female Participants Investigating the Effect of TMC435 on the Pharmacokinetics of the Synthetic Hormones of the Oral Contraceptive OvysmenCompletedNCT01486004Phase 1

  Sponsor listed in the registry: Tibotec Pharmaceuticals, Ireland · First submitted after Tibotec Pharmaceuticals, Ireland became part of Johnson & Johnson

• TMC125HIV1083 - Swallowability of Uncoated 200 mg Etravirine Tablets in HIV-1 Infected PatientsCompletedNCT01090648Phase 1

  Sponsor listed in the registry: Tibotec Pharmaceuticals, Ireland · First submitted after Tibotec Pharmaceuticals, Ireland became part of Johnson & Johnson

• TMC435-TiDP16-C108 - A Study in Healthy Volunteers Investigating the Pharmacokinetic Interaction Between TMC435 and Digoxin and Between TMC435 and RosuvastatinCompletedNCT01288742Phase 1

  Sponsor listed in the registry: Tibotec Pharmaceuticals, Ireland · First submitted after Tibotec Pharmaceuticals, Ireland became part of Johnson & Johnson

• TMC435-TiDP16-C114 - A Study in Healthy Volunteers Investigating the Pharmacokinetic Interaction Between TMC435 and the Antiretroviral Agents TMC278 and TenofovirCompletedNCT01205139Phase 1

  Sponsor listed in the registry: Tibotec Pharmaceuticals, Ireland · First submitted after Tibotec Pharmaceuticals, Ireland became part of Johnson & Johnson

• TMC278-TiDP15-C158 - A Study to Examine the Safety, Tolerability and Pharmacokinetics of a Single Dose or Three Successive Doses of Intramuscularly (IM) Injected Long Acting Formulation of TMC278CompletedNCT01031589Phase 1

  Sponsor listed in the registry: Tibotec Pharmaceuticals, Ireland · First submitted after Tibotec Pharmaceuticals, Ireland became part of Johnson & Johnson

• TMC435-TiDP16-C123 - A Study in Healthy Volunteers Investigating the Pharmacokinetic Interaction Between TMC435 and the Antiretroviral Agents Efavirenz and RaltegravirCompletedNCT01241773Phase 1

  Sponsor listed in the registry: Tibotec Pharmaceuticals, Ireland · First submitted after Tibotec Pharmaceuticals, Ireland became part of Johnson & Johnson

• A Study in Healthy Participants Investigating the Effect of TMC435 on the Pharmacokinetics of Immunosuppressants Cyclosporine and TacrolimusCompletedNCT01479881Phase 1

  Sponsor listed in the registry: Tibotec Pharmaceuticals, Ireland · First submitted after Tibotec Pharmaceuticals, Ireland became part of Johnson & Johnson

• TMC435-TiDP16-C115 - A Study in Healthy Volunteers Investigating the Pharmacokinetic Interaction Between TMC435 and Erythromycin and Between TMC435 and Darunavir/Ritonavir (DRV/r)CompletedNCT01323257Phase 1

  Sponsor listed in the registry: Tibotec Pharmaceuticals, Ireland · First submitted after Tibotec Pharmaceuticals, Ireland became part of Johnson & Johnson

• TMC435-TiDP16-C116 - Relative Bioavailability and Food Effect StudyCompletedNCT01308606Phase 1

  Sponsor listed in the registry: Tibotec Pharmaceuticals, Ireland · First submitted after Tibotec Pharmaceuticals, Ireland became part of Johnson & Johnson

• A Study to Evaluate Antiviral Activity of Darunavir + Ritonavir in HIV-1 Infected AdolescentsCompletedNCT00915655Phase 2

  Sponsor listed in the registry: Tibotec Pharmaceuticals, Ireland · First submitted after Tibotec Pharmaceuticals, Ireland became part of Johnson & Johnson

• TMC125IFD1001 - Drug-Drug Interaction of Etravirine With Telaprevir and TMC278 With Telaprevir.CompletedNCT01336829Phase 1

  Sponsor listed in the registry: Tibotec Pharmaceuticals, Ireland · First submitted after Tibotec Pharmaceuticals, Ireland became part of Johnson & Johnson

• TMC278-TiDP6-C153 - A Study in Healthy Volunteers Investigating the Pharmacokinetic Interaction Between TMC278 and RaltegravirCompletedNCT01288755Phase 1

  Sponsor listed in the registry: Tibotec Pharmaceuticals, Ireland · First submitted after Tibotec Pharmaceuticals, Ireland became part of Johnson & Johnson

• TMC125-C216: A Phase III Study to Investigate the Efficacy, Tolerability and Safety of TMC125 as Part of an Antiretroviral Regimen, Including TMC114/Ritonavir and an Investigator-selected Optimized Background, in HIV-1 Infected Patients With Limited to no Treatment Options.CompletedNCT00255099Phase 3

  Sponsor listed in the registry: Tibotec Pharmaceuticals, Ireland · First submitted after Tibotec Pharmaceuticals, Ireland became part of Johnson & Johnson